Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-NY ESO 1 CAR-T cell therapy - Eutilex

Next Previous
Drug Profile

Anti-NY ESO 1 CAR-T cell therapy - Eutilex

Alternative Names: New York oesophageal squamous cell carcinoma-1 antigen-induced natural T cell therapy - Eutilex

Latest Information Update: 26 Dec 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eutilex
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Sarcoma

Most Recent Events

  • 26 Dec 2022 No development reported - Phase-II for Sarcoma (Recurrent, Second-line therapy or greater) in South Korea (IV) (Eutilex pipeline, December 2022)
  • 06 Aug 2020 Eutilex completes a phase II trial in Sarcoma (Recurrent, Second-line therapy or greater) in South Korea (IV) before August 2020 (Eutilex pipeline, August 2020)
  • 06 Aug 2020 Phase-II clinical trials in Sarcoma (Recurrent, Second-line therapy or greater) in South Korea (IV) before August 2020 (Eutilex pipeline, August 2020)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top